Vol. 5 (09) pp. 403-405 DOI: 10.21474/IJAR01/5343

REFRACTORY THROMOBOTIC ANTI-PHOSPHOLIPID SYNDROME MANIFESTING WITH BUDD CHIARI SYNDROME AND PULMONARY EMBOLISM.

, , , , and
  • Department of Medicine, King Fahad Specialist Hospital-Dammam, Saudi Arabia.
18 Downloads 142 Views
Crossref

Download Full Paper (PDF)

Keywords

Article Analytics

References

  1. Chighizola C, Ubiali T, Meroni P. Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management?An Insight into Future Approaches.?Journal of Immunology Research. 2015;2015:1-20. doi:10.1155/2015/951424.
  2. MIYAKIS S, LOCKSHIN M, ATSUMI T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).?Journal of Thrombosis and Haemostasis. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x.
  3. Roubey R. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice.?Lupus. 2010;19(4):440-445. doi:10.1177/0961203310361356.
  4. Scoble T, Wijetilleka S, Khamashta M. Management of refractory anti-phospholipid syndrome.?Autoimmunity Reviews. 2011;10(11):669-673. doi:10.1016/j.autrev.2011.04.030.
  5. Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows.?Nature Reviews Rheumatology. 2015;11(10):586-596. doi:10.1038/nrrheum.2015.88.
  6. Crowther M, Ginsberg J, Julian J. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.?ACC Current Journal Review. 2004;13(1):15. doi:10.1016/j.accreview.2003.10.079.

How to Cite This Article

Sherif A. Nasef, , Amer S. Zahralliyali, Mazen A. Elyahia, Ahmed Y. Alothman and Hanan M.Alrammah (2017); REFRACTORY THROMOBOTIC ANTI-PHOSPHOLIPID SYNDROME MANIFESTING WITH BUDD CHIARI SYNDROME AND PULMONARY EMBOLISM., Int. J. of Adv. Res., 5 (09), 403-405, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/5343

Corresponding Author

Amer S. Zahralliyali

Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.